drugset / Trial / NCT00622401
Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12
Phase 1/2
Terminated
8 enrolled
Beth Israel Deaconess Medical Center
Brigham and Women's Hospital · collabDana-Farber Cancer Institute · collabHarvard Medical School (HMS and HSDM) · collabNational Cancer Institute (NCI) · collabUnited States Department of Defense · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the safety of an investigational Dendritic Cell/Tumor Fusion vaccine given with IL-12 for patients with breast cancer. RATIONALE: Vaccines made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells. Interleukin-12 may stimulate the white blood cells to kill tumor cells. Giving vaccine therapy together with interleukin-12 may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of interleukin-12 when given together with vaccine therapy and to see how well they work in treating women with stage IV breast cancer.
Timeline
- Start
- 2009-12
- Primary completion
- 2014-10
- Completion
- 2014-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dendritic Cell/Tumor Fusion Vaccine | Vaccine | — | Subcutaneous |
| Subject | interleukin-12 | Protein / enzyme biologic | 30 ng | Subcutaneous |
| Subject | interleukin-12 | Protein / enzyme biologic | 100 ng | Subcutaneous |